Christopher Downs - 29 Mar 2023 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Reporting relationship: Chief Financial Officer
Issuer ticker: CNSP
Reported as of: 29 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Mar 2023, 19:28:10 UTC
Prior SEC filing: 10 Feb 2023
Next SEC filing: 18 Apr 2023
Source filing: View source filing
Reporting owner signature: /s/ Christopher Downs

Key filing fact

Christopher Downs filed Form 4 for CNS Pharmaceuticals, Inc. (CNSP) on 31 Mar 2023.

Key facts

This page summarizes Christopher Downs's Form 4 filing for CNS Pharmaceuticals, Inc. (CNSP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 31 Mar 2023, 19:28.

Change

Previous filing in this sequence was filed on 10 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNSP transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +6,067
Change %: +27%
Price
Shares after: 28,768
Date: 29 Mar 2023
Ownership: Direct
Underlying class: Common stock
Underlying amount: 6,067
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock.

Footnote F2

The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 50% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $6.00 (subject to pro rata adjustment for stock splits or similar events); and (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $24.00 (subject to pro rata adjustment for stock splits or similar events).

Footnote F3

Issued in connection with the reporting person's employment with the Company.